Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285992457> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W4285992457 endingPage "S35" @default.
- W4285992457 startingPage "S35" @default.
- W4285992457 abstract "Acne is the most common skin condition in the United States, affecting up to 90% of people at some point in their lives. It is frequently accompanied by post-inflammatory hyperpigmentation, which affects skin of color with greater severity. Tetracyclines are the most widely prescribed oral antibiotics for acne and have been proven effective against moderate to severe inflammatory subtypes, but previous studies have shown that tetracyclines are independently associated with hyperpigmentation. Given their antagonistic anti-inflammatory and pro-hyperpigmentation effects, it is important to characterize the risk of hyperpigmentation associated with tetracyclines in different skin types. Using retrospective data collected from 44 institutions in the TriNetX database, we identified 1,018,736 patients with a diagnosis of acne. From this cohort, we identified patients who were prescribed doxycycline (n=150,715), minocycline (n=43,975), and cephalexin (n=38,112) as an oral antibiotic monotherapy. Patients diagnosed with melasma or prescribed isotretinoin at any time were excluded. Patients with a prior history of hyperpigmentation were also excluded. In our study, patients given doxycycline (OR 1.66, p<0.0001) and minocycline (OR 1.58, p<0.0001) were more likely to have developed new hyperpigmentation compared to those given cephalexin. Among different racial groups, the odds of new hyperpigmentation associated with doxycycline versus cephalexin was highest in Hispanics (White: OR 1.19, p=0.018; Black: OR 1.54, p=0.001; Hispanic: OR 1.90, p=0.001; Asian: OR 1.35, p=0.337). The odds associated with minocycline versus cephalexin was highest in Blacks (White: OR 1.23, p=0.008; Black: OR 1.44, p=0.009; Hispanic: OR 1.00, p=0.991; Asian: OR 1.09, p=0.785). Our results suggest that doxycycline and minocycline are risk factors for new hyperpigmentation in acne patients of all racial groups. These associations should be taken into consideration when prescribing acne treatment regimens." @default.
- W4285992457 created "2022-07-21" @default.
- W4285992457 creator A5000878763 @default.
- W4285992457 creator A5015504063 @default.
- W4285992457 creator A5040844032 @default.
- W4285992457 creator A5044873455 @default.
- W4285992457 creator A5059337514 @default.
- W4285992457 creator A5080852603 @default.
- W4285992457 creator A5083248682 @default.
- W4285992457 date "2022-08-01" @default.
- W4285992457 modified "2023-09-28" @default.
- W4285992457 title "206 Tetracyclines are associated with development of new hyperpigmentation in acne patients" @default.
- W4285992457 doi "https://doi.org/10.1016/j.jid.2022.05.213" @default.
- W4285992457 hasPublicationYear "2022" @default.
- W4285992457 type Work @default.
- W4285992457 citedByCount "0" @default.
- W4285992457 crossrefType "journal-article" @default.
- W4285992457 hasAuthorship W4285992457A5000878763 @default.
- W4285992457 hasAuthorship W4285992457A5015504063 @default.
- W4285992457 hasAuthorship W4285992457A5040844032 @default.
- W4285992457 hasAuthorship W4285992457A5044873455 @default.
- W4285992457 hasAuthorship W4285992457A5059337514 @default.
- W4285992457 hasAuthorship W4285992457A5080852603 @default.
- W4285992457 hasAuthorship W4285992457A5083248682 @default.
- W4285992457 hasBestOaLocation W42859924571 @default.
- W4285992457 hasConcept C126322002 @default.
- W4285992457 hasConcept C156957248 @default.
- W4285992457 hasConcept C16005928 @default.
- W4285992457 hasConcept C2776677263 @default.
- W4285992457 hasConcept C2776728111 @default.
- W4285992457 hasConcept C2777179404 @default.
- W4285992457 hasConcept C2777673923 @default.
- W4285992457 hasConcept C2778275353 @default.
- W4285992457 hasConcept C2909381827 @default.
- W4285992457 hasConcept C501593827 @default.
- W4285992457 hasConcept C71924100 @default.
- W4285992457 hasConcept C86803240 @default.
- W4285992457 hasConcept C89423630 @default.
- W4285992457 hasConceptScore W4285992457C126322002 @default.
- W4285992457 hasConceptScore W4285992457C156957248 @default.
- W4285992457 hasConceptScore W4285992457C16005928 @default.
- W4285992457 hasConceptScore W4285992457C2776677263 @default.
- W4285992457 hasConceptScore W4285992457C2776728111 @default.
- W4285992457 hasConceptScore W4285992457C2777179404 @default.
- W4285992457 hasConceptScore W4285992457C2777673923 @default.
- W4285992457 hasConceptScore W4285992457C2778275353 @default.
- W4285992457 hasConceptScore W4285992457C2909381827 @default.
- W4285992457 hasConceptScore W4285992457C501593827 @default.
- W4285992457 hasConceptScore W4285992457C71924100 @default.
- W4285992457 hasConceptScore W4285992457C86803240 @default.
- W4285992457 hasConceptScore W4285992457C89423630 @default.
- W4285992457 hasIssue "8" @default.
- W4285992457 hasLocation W42859924571 @default.
- W4285992457 hasOpenAccess W4285992457 @default.
- W4285992457 hasPrimaryLocation W42859924571 @default.
- W4285992457 hasRelatedWork W1522520075 @default.
- W4285992457 hasRelatedWork W1966553259 @default.
- W4285992457 hasRelatedWork W2413614809 @default.
- W4285992457 hasRelatedWork W2552572772 @default.
- W4285992457 hasRelatedWork W3018679789 @default.
- W4285992457 hasRelatedWork W3130678330 @default.
- W4285992457 hasRelatedWork W3194975421 @default.
- W4285992457 hasRelatedWork W3214446229 @default.
- W4285992457 hasRelatedWork W4226456704 @default.
- W4285992457 hasRelatedWork W4247764565 @default.
- W4285992457 hasVolume "142" @default.
- W4285992457 isParatext "false" @default.
- W4285992457 isRetracted "false" @default.
- W4285992457 workType "article" @default.